Lung Cancer
An Evidence-Based Approach to Multidisciplinary Management
- 1st Edition - August 24, 2023
- Imprint: Elsevier
- Editors: Erin Alexis Gillaspie, Leora Horn, Amanda S. Cass
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 6 9 5 7 3 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 6 9 5 7 4 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 5 2 3 - 3
Care of the lung cancer patient—screening, diagnosis, and treatment—has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCare of the lung cancer patient—screening, diagnosis, and treatment—has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management covers every aspect of this fast-changing field, including new screening guidelines, new practice standards, and new treatment advances that have led to higher survival rates. This practical, clinically oriented resource provides thorough, evidence-based coverage from experts in the field, including the increasingly important precision medicine approach in lung cancer planning and management.
-
Discusses key topics such as small cell and non-small cell lung cancers; immunotherapy, molecular cohorts including ROS1, BRAF, HER2, Met, and NTRK; oligometastatic disease; and more.
-
Covers individualized treatment plans for chemotherapy, radiotherapy, targeted biomarker-derived therapies, and new and emerging immunotherapies.
-
Provides excellent visual guidance throughout, including algorithms, pathology specimens, anatomic drawings, and PET/CT and CT imaging for diagnosis and treatment planning.
-
Features “Top 5 Clinical Pearls” at the beginning of each chapter.
-
Shares the experience and knowledge of medical oncologists, radiation oncologists, surgical oncologists, and thoracic radiologists for a real-world tumor board perspective.
-
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.
Medical oncologists, thoracic oncologists, pulmonologists, oncology and pulmonology fellows
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Preface
- List of Contributors
- List of Illustrations
- List of Tables
- 1. Lung cancer screening and prevention
- Epidemiology, risk factors, and prevention of lung cancer
- History and evolution of lung cancer screening
- Pros and cons of lung cancer screening
- Current screening eligibility guidelines and recommendations
- Cost effectiveness of lung cancer screening
- Implementation of lung cancer screening
- Current status of lung cancer screening
- Future directions of lung cancer screening
- References
- 2. Lung cancer: Diagnostic techniques
- Introduction
- Approach to diagnosis and staging of lung cancer
- Staging of lung cancer: Noninvasive methods
- Diagnosis and staging of lung cancer
- Bronchoscopic techniques for lung biopsy
- Novel techniques for diagnosis of lung nodules
- Cone-beam computed tomography
- Image-guided percutaneous diagnosis
- Pleural-based procedures
- New and emerging strategies for diagnosis and risk stratification
- Conclusion
- References
- 3. Histology and molecular testing
- Introduction
- Pulmonary adenocarcinoma
- Clinical and prognostic relevance of adenocarcinoma subtypes
- Squamous cell carcinoma
- Neuroendocrine carcinomas
- Other pulmonary carcinomas
- Pathological staging of lung carcinoma—AJCC 8th edition
- Predictive biomarker and molecular testing
- Testing algorithm
- Testing methods and assays
- Selecting samples for testing
- Lung cancer patients requiring biomarker testing
- Timing of biomarker testing
- Future perspective
- References
- 4. Surgical considerations in lung cancer treatment
- Introduction
- Operative procedures
- Approach to treatment selection
- Conclusions
- References
- 5. Surgically resectable disease
- Introduction
- Clinical stages I and II
- Clinical stage III
- Special surgical considerations
- Conclusion
- References
- 6. Oligometastatic disease
- Introduction
- Treatment
- Prognostic factors
- Future directions
- Suggested Reading
- References
- 7. Locally advanced non–small cell lung cancer
- Introduction
- Treatment of patients with potentially resectable disease
- Radiation therapy considerations for unresectable disease
- Chemotherapy considerations for unresectable disease
- Targeted therapies in locally advanced NSCLC
- Immunotherapy in locally advanced NSCLC
- Conclusions
- References
- 8. First-line therapy
- Anti-PD-1/PD-L1 monotherapy as first-line therapy in patients with advanced non–small cell lung cancer without oncogenic drivers (EGFR, ALK wild type)
- Anti-PD-1/PD-L1 combinations with chemotherapy as first-line treatment in patients with advanced NSCLC
- Checkpoint inhibitor combinations
- Additional considerations
- Selecting the optimal chemotherapy regimen
- Conclusion
- References
- 9. Second-line therapy in advanced non–small cell lung cancer
- Introduction
- Cytotoxic chemotherapy
- Immunotherapy
- Biomarkers of immune checkpoint inhibitor benefit
- Management of disease progression after front-line immunotherapy
- Ongoing clinical trials
- Conclusions
- References
- 10. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach
- Introduction and epidemiology
- Molecular pathways and mutations
- Molecular testing at diagnosis
- Overview of generation of EGFR tyrosine kinase inhibitors
- Current treatment paradigm
- EGFR tyrosine kinase inhibitors and resistance mechanisms
- Current therapeutic challenges and considerations
- Conclusions and future directions
- References
- 11. Diagnosis a nd treatment of anaplastic lymphoma kinase (ALK) rearranged non−small cell lung cancer
- Introduction
- Diagnosis
- Staging
- First-line treatment for metastatic disease
- Central nervous system disease
- Disease progression
- Clinical management
- Future directions
- Conclusions
- References
- 12. Other molecular cohorts including ROS1, BRAF, HER2, MET, NT RK, RET, KRAS
- Introduction
- ROS-1
- BRAF
- MET
- RET
- HER-2
- NTRK
- KRAS
- Conclusions
- References
- 13. Immunotherapy
- Single-agent immunotherapy
- Combination IO/IO or Chemotherapy/IO
- Assessment of response
- Safety and toxicity management
- References
- 14. Small cell lung cancer
- Introduction
- Clinical presentation and classification
- Therapeutic management of small cell lung cancer
- Conclusion
- References
- Index
- Edition: 1
- Published: August 24, 2023
- Imprint: Elsevier
- No. of pages: 512
- Language: English
- Hardback ISBN: 9780323695732
- eBook ISBN: 9780323695749
- eBook ISBN: 9780443285233
Read Lung Cancer on ScienceDirect